Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,397,756 papers from all fields of science
Search
Sign In
Create Free Account
ECOG Performance Status 1
Known as:
ECOG 1
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Concurrent chemoradiotherapy for head and neck cancers in older patients: Outcomes and their determinants
V. Srinivasalu
,
N. Subramaniam
,
+9 authors
P. Keechilat
Indian Journal of Cancer
2019
Corpus ID: 198168537
INTRODUCTION: Meta-analyses have shown concurrent chemoradiotherapy (CCRT) provides no survival benefit over radiotherapy in…
Expand
2018
2018
Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
B. Escudier
,
P. Barthélémy
,
A. Ravaud
,
S. Négrier
,
M. Needle
,
L. Albiges
2018
Corpus ID: 80235878
618Background: Tivozanib is a VEGFR-TKI with high specificity and lower incidence of class effect adverse events. As combinations…
Expand
Review
2016
Review
2016
DI-003 Paclitaxel-carboplatin induced peripheral neuropathy in ovarian cancer patients
M. Petrusevska
,
B. Petreska
,
K. Mladenovska
,
S. Veljanoska
2016
Corpus ID: 77521840
Background Administration of paclitaxel is associated with an increased survival rate in ovarian cancer patients. Despite the…
Expand
2013
2013
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
A. Naeim
,
P. Ward
,
+8 authors
J. Hecht
Journal of Geriatric Oncology
2013
Corpus ID: 22242221
2012
2012
A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer.
M. Nasim
,
R. Plummer
,
+11 authors
C. Twelves
2012
Corpus ID: 220745742
2552 Background: Eribulin mesylate is a microtubule dynamics inhibitor approved by FDA for patients (pts) with metastatic breast…
Expand
2012
2012
Physical function and quality of life in frail and/or elderly metastatic colorectal cancer patients treated with bevacizumab and capecitabine: An exploratory analysis.
P. Ward
,
A. Liem
,
+6 authors
A. Naeim
Journal of Clinical Oncology
2012
Corpus ID: 19665792
627 Background: Optimal treatment strategies in frail and/or elderly patients with metastatic colorectal cancer have not been…
Expand
2011
2011
MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: Apreliminary report.
E. Efstathiou
,
M. Titus
,
+8 authors
C. Logothetis
Journal of Clinical Oncology
2011
Corpus ID: 42907449
4501 Background: "Intracrine" androgen signaling is linked to castrate-resistant prostate cancer (CRPC) and a "credentialed…
Expand
2009
2009
Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto).
D. Danila
,
J. S. D. Bono
,
+7 authors
H. Scher
Journal of Clinical Oncology
2009
Corpus ID: 1700334
5048 Background: AA is a potent blocker of CYP17, required for synthesis of testosterone in the testes, adrenals, and prostate…
Expand
2004
2004
Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial…
M. Dickler
,
H. Rugo
,
+7 authors
C. Hudis
Journal of Clinical Oncology
2004
Corpus ID: 44965971
2001 Background: Aberrant VEGFR expression in breast tumor cells and EGFR expression in endothelial cells may contribute to tumor…
Expand
2002
2002
Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer.
S. Kim
,
H. Sung
,
+10 authors
Jun Suk Kim
Cancer research and treatment : official journal…
2002
Corpus ID: 25584886
PURPOSE The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE